Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cross-sectional Study on the Efficacy and Safety of the Combination of Daratumumab+Bortezomib+Dexamethasone Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease

NCT06297681 is registered in ClinicalTrials.gov with Beijing Chao Yang Hospital as lead sponsor.

NCT NCT06297681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06297681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cross-sectional Study on the Efficacy and Safety of the Combination of Daratumumab+Bortezomib+Dexamethasone Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease
Lead sponsor
Beijing Chao Yang Hospital
Phase
Observational
Overall status
Unknown status
Start date
March 15, 2024
Completion date
December 31, 2025
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

m-protein related cardiac disease